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Abstract

Pneumonia is a common disease-causing hospitalization. When a healthcare-associated infection is suspected, antibiotics that
provide coverage for multi-drug resistant (MDR) or extended-spectrum beta-lactamase (ESBL) bacteria are frequently prescribed.
Limited data is available for guidance on using meropenem as a ﬁrst-line empiric antimicrobial in hospitalized patients with risk factors
for MDR/ESBL bacterial infections.
This was a single-center, retrospective study designed and conducted to identify factors associated with positive cultures for
MDR/ESBL pathogens in hospitalized patients with suspected healthcare-associated pneumonia.
Of the 246 patients, 103 patients (41%) received meropenem. Among patients prescribed meropenem, MDR/ESBL pathogens
were detected in only 20 patients (13%). Patients admitted from a skilled nursing facility/long-term acute care (SNF/LTAC) or with a
history of a positive culture for MDR/ESBL pathogens were signiﬁcantly associated with positive cultures of MDR/ESBL pathogens
during the hospitalization (odds ratio [95% conﬁdence intervals], 31.40 [5.20–189.6] in SNF/LTAC and 18.50 [2.98–115.1] in history
of culture-positive MDR/ESBL pathogen). There was no signiﬁcant difference in mortality between the 3 antibiotic groups.
Admission from a SNF/LTAC or having a history of cultures positive for MDR/ESBL pathogens were signiﬁcantly associated with a
positive culture for MDR/ESBL pathogens during the subsequent admission. We did not detect signiﬁcant association between
meropenem use as a ﬁrst-line drug and morbidity and mortality for patients admitted to the hospital with suspected healthcareassociated pneumonia, and further prospective studies with larger sample size are needed to conﬁrm our ﬁndings.
Abbreviations: CAP = community acquired pneumonia, CI = conﬁdence interval, ESBL = extended-spectrum beta-lactamase,
HCAP = healthcare-associated pneumonia, HL = Hosmer–Lemeshow test, ICU = intensive care unit, LTAC = long-term acute care,
MDR = multi-drug resistant, OR = odds ratio, SIRS = systemic inﬂammatory response syndrome score, SNF = skilled nursing facility.
Keywords: antibiotic stewardship, antibiotics, carbapenem, drug resistance, pneumonia

lence of multi-drug resistant (MDR) or extended-spectrum betalactamase (ESBL) organisms and the subgroups of MDR/ESBL
organisms such as carbapenem-resistant enterobacteriaceae are
raising public health concerns as these bacteria are associated
with higher rates of morbidity and mortality.[3]

1. Introduction
Bacterial resistance to antibiotics is a severe global health
concern.[1] Every year at least 4 million people acquire an
infection with resistant bacteria, and about 23,000 people die
from the associated complications.[2] More recently the prevaEditor: Shreedhar Kulkarni.
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from a skilled nursing facility (SNF) or LTAC, history of
tracheostomy, history of hemiplegia/paraplegia, age, Charlson
comorbidity index, history of cultures positive for MDR/ESBL
pathogens, history of multiple hospital admissions in the last 6
months, no risk factors for healthcare-associated infections, sex
(male), and systemic inﬂammatory response syndrome score
(SIRS)[11] as previously described by others.[12,13] Mean SIRS
scores on day 1 and day 3 of hospitalization were compared with
nonparametric tests (the Wilcoxon Signed Rank Test) for related
samples. Use of at least 1 dose of meropenem was assessed to
compare with cefepime or piperacillin/tazobactam whether it was
associated with changing patients’ clinical outcomes such as
overall mortality rate, in-hospital mortality rate, readmission
rate, median length of hospital day, median length of ICU days,
and median length of ventilator days in the subgroup of intubated
patients. In all these analyses, the following factors were assessed
to see if they might confound the relationship: age, sex, body
mass index, Charlson comorbidity index, risk of mortality based
on Mortality Probability Model III at zero hours score,[14] and
SIRS score. Analyses were performed utilizing SPSS (version 25;
IBM Corp., Armonk, NY) and R (version 3.6.1; R-project,
Vienna, Austria).

Although comprehensive data on the appropriateness of
inpatient antibiotic use is lacking in the United States,[4] 1 study
found that 37% of antibiotics prescribed in sample hospitals
across the country were potentially unnecessary.[5] Inappropriate
antibiotic use is associated with poor clinical outcomes and an
increase in public health burdens, such as adverse drug reactions,
the emergence of resistant pathogens, and cost.[6] In many cases,
physicians prescribe broad-spectrum antibiotics for presumed
infections with MDR strains of bacteria. However, ultra-broad
spectrum antibiotics such as carbapenems (meropenem) may be
prescribed in fear of providing inadequate initial coverage since
data for the management of sepsis has shown inadequate initial
coverage is linked with signiﬁcant increases in mortality.[7–9] This
study was designed to explore factors associated with MDR/
ESBL pathogens in patients admitted with the diagnosis of
healthcare-associated pneumonia (HCAP).

2. Methods
2.1. Study design, setting, and population
This study was approved with a waiver of informed consent by
the Institutional Review Board of University of Nevada Las
Vegas, Nevada (IRB No 1198024-1) and University Medical
Center of Southern Nevada, Las Vegas, Nevada (IRB No UMC2017-115).
We retrospectively analyzed data from an urban-based tertiary
care teaching hospital from April 1 to December 31, 2018.
Enrolled patients were 18 years or older and admitted to the
medical/surgical care unit and medical intensive care unit (ICU)
with a primary diagnosis of HCAP. The medical/surgical care
unit is staffed with internal medicine and family medicine
attending physicians, medical residents, and hospitalists The ICU
is staffed with internal medicine residents, pulmonary/critical
care fellows and attending physicians. The clinical diagnosis was
made by the emergency department physicians and primary care
teams at admission and documented in the patients’ chart.
Patients were categorized into 3 groups identiﬁed as meropenem,
cefepime, or piperacillin/tazobactam reﬂecting the initial antibiotic received. All patients empirically received an intravenous
vancomycin dose to cover a presumed methicillin-resistant
Staphylococcus Aureus infection. Cultures of sputum, blood,
and urine taken during hospital admission were evaluated and
patients with a primary infectious diagnosis other than HCAP
such as gastrointestinal, skin, and urinary tract infection were
excluded.
All patients were assessed to determine if they met the criteria
of HCAP deﬁned as hospitalization for at least 48 hours in the last
90 days, residence of a nursing home or long-term acute care
(LTAC), received intravenous antibiotics, chemotherapy or
wound care within the past 30 days, or attended a hemodialysis
clinic.[10] Furthermore, as to not inﬂuence the clinical decisionmaking process, the admitting team was not aware that their
diagnoses and antibiotic choices were being monitored.

3. Results
3.1. Cohort and encounter characteristics
During the study period, 1156 patients were admitted to the
hospital with a primary diagnosis of a healthcare acquired
infection (Fig. 1). Of these, 910 patients were excluded due to a
diagnosis of gastrointestinal, skin, or urinary tract infections, and
235 were excluded for other reasons. The remaining 246 patients
had a diagnosis of HCAP who received meropenem (103 [41%]),
cefepime (88 [36%]), or piperacillin/tazobactam (55 [22%]).
Among the meropenem group, 50 were admitted to the ICU, and
35 underwent mechanical ventilation. Of the patients who
received cefepime and piperacillin/tazobactam, 37 and 24,
respectively, were admitted to the ICU, with 30 and 15
mechanically ventilated, respectively.
Characteristics of the study population are shown in Table 1.
There were no signiﬁcant differences between groups in age, sex,
body mass index, MPM 0 score, history of tracheostomy,
Charlson comorbidity index, hemiplegia/paraplegia, and SIRS
score during the admission. The solid malignancy rate was
signiﬁcantly higher in the meropenem group (meropenem 26
[25%], piperacillin/tazobactam 9 [16%], cefepime 9 [10%];
P = .028). The admission rate from a SNF/LTAC was the highest
in meropenem group (meropenem: 38 [37%], cefepime; 15
[17%], piperacillin/tazobactam: 11 [20%]; P = .004). The history
of MDR/ESBL infection/colonization rate was highest in
meropenem group but not statistically signiﬁcant (meropenem:
10 [9.7%], cefepime: 2 [2.3%], piperacillin/tazobactam 3
[5.6%]; P = .101).
Antibiotics prescription pattern and percentage of HCAP
exclusion are shown in Table 5. More than 40% of each
antibiotic was changed on day 1 (meropenem: 24 [43.6%],
cefepime: 42 [47.4%], piperacillin/tazobactam: 24 [43.6%];
P = .404). HCAP exclusion percentage at the time of discharge
from the hospital was the highest in piperacillin/tazobactam but
not statistically signiﬁcant (meropenem: 15 [14.6%], cefepime:
18 [20.5%], piperacillin/tazobactam: 17 [30.9%]). Comparison
of clinical response on day 1 and day 3 done by SIRS score is

2.2. Statistical analysis
Continuous variables were compared using the Kruskal–Wallis
test, and categorical variables were analyzed using a crosstabulation chi-square test. To determine the independent risk
factors for developing MDR/ESBL organisms in the cultures,
logistic regression was used to test the following factors: admitted
2
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Figure 1. Cohort study ﬂow diagram. All study groups received intravenous vancomycin during the admission. ED = emergency department, GI = gastrointestinal,
ICU = intensive care unit.

group, 31 (30%) of patients did not meet the criteria for HCAP as
deﬁned in the methodology, and regardless of the antibiotic group,
more than one-third of the patients diagnosed with HCAP had only
community acquired pneumonia (CAP) criteria (Table 1).
Signiﬁcant predictors for developing MDR/ESBL organisms in
cultures were admission from a SNF/LTAC, (odds ratio [OR],
23.29; 95% conﬁdence interval [CI], 3.59–151.4; P = .001) and
history of a positive culture for MDR/ESBL organisms (OR,
18.35; 95% CI, 2.88–117.1; P = .002) (Table 3). However, the
rest of the variables were not signiﬁcantly associated with
developing MDR/ESBL pathogens. The Hosmer–Lemeshow test
(HL) was not signiﬁcant (HL = 5.513, P = .741), which indicates
that the model was adequate. However, it should be noted that
the OR and CI were wide, indicating a large standard error; this is
often due to small sample sizes, and hence these results should be
interpreted with that caveat in mind. Among the 3 groups, there
was no signiﬁcant difference in overall mortality (meropenem,
16%; cefepime, 18%; piperacillin/tazobactam, 9.3%; P = .349).

shown in Table 6. There was no signiﬁcant difference between
day 1 and day 3 SIRS scores of each antibiotic group.
3.2. Microbial etiology
All culture samples were collected as a part of our hospital sepsis
bundle on day 1. The overall results of microbial aetiology in the
group of each antibiotic given in Table 2. The proportion of
MDR/ESBL pathogens was signiﬁcantly higher in the meropenem
group (13%) compared to cefepime (5.6%) or piperacillin/
tazobactam (3.6%) group (P = .012). In the meropenem group,
7.8% of organisms were carbapenem-resistant.
3.3. Prescribing pattern of ultra-broad spectrum
antibiotics (carbapenem) and predictors for developing
MDR/ESBL organisms
As expected, a large portion of study patients (42%) with a
diagnosis of HCAP received meropenem. Within the meropenem
3
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Table 1
Baseline demographic and clinical characteristics of patients by type of antibiotics.
Cefepime
(n = 88)
Age, years
Sex, male
BMI, kg/m2
MPM 0, %
SIRS, categories
0
1
2
3
4
No risk factor for healthcare-associated infection
Resident of SNIF/LTAC
History of tracheostomy
History of MDR/ESBL infection
∗
Charlson comorbidity index
Arrhythmia
Coronary artery disease
Congestive heart failure
Chronic kidney disease
Chronic obstructive lung disease
Dementia
Hemiplegia/paraplegia
Hypertension
Leukemia/lymphoma
Liver disease
Solid malignancy
Peptic ulcer disease
Peripheral vascular disease

Piperacillin/tazobactam
(n = 55)

Meropenem
(n = 103)

60
58
25
58

(48–70)
(65)
(22–32)
(22.3–80.0)

55
34
25
33

(46–68)
(62)
(21–32)
(16.9–58.6)

61
53
25
47

(50–73)
(51)
(22–30)
(20.6–67.7)

23
40
18
2
5
52
15
8
2
4
8
8
12
16
20
10
14
43
3
4
9
1
2

(26.1)
(45.5)
(20.5)
(2.3)
(5.7)
(59)
(17)
(9.1)
(2.3)
(2–6)
(9)
(9)
(14)
(18)
(23)
(11)
(15.9)
(49)
(3)
(5)
(10)
(1)
(2)

21
19
8
2
4
19
11
1
3
4
3
10
7
9
9
3
5
29
1
5
9
4
0

(38.9)
(35.2)
(14.8)
(3.7)
(7.4)
(35)
(20)
(1.8)
(5.6)
(2–6)
(5)
(18)
(13)
(16)
(16)
(5)
(9.3)
(52)
(2)
(9)
(16)
(7)
(0)

29
46
16
0
12
31
38
10
10
5
15
12
1
20
26
16
7
38
5
0
26
2
1

(28.2)
(44.7)
(15.5)
(0)
(11.7)
(30)
(37)
(9.7)
(9.7)
(3–7)
(15)
(12)
(1)
(19)
(25)
(16)
(6.8)
(37)
(5)
(0)
(25)
(2)
(1)

P-value
.478
.121
.813
.461
.236

<.001
.004
.102
.101
.228
.187
.245
.443
.913
.119
.183
.123
.119
.629
.518
.028
.072
.468

Values are median (IQR) or number of patients (%).
BMI = body mass index, ESBL = extended-spectrum beta-lactamase, IQR = interquartile range, LTAC = long term acute care, MDR = multi-drug resistant, MPM 0 = mortality probability model III at 0 hours,
SIRS = systemic inﬂammatory response syndrome, SNF = skilled nursing facility.
∗
Harlson comorbidity index take into account following comorbidities: from arrhythmia to peripheral vascular disease.

high risk for MDR organisms because of a history of exposure to
the healthcare system.[10] In 2016, the guideline removed the term
HCAP because the presence of MDR organisms was not found to
be associated with risk factors for HCAP. One prospective study
in a Spanish ICU found that 90% of patients diagnosed with
HCAP could have been appropriately treated with therapy for
CAP using antibiotics such as ceftriaxone and azithromycin.[16]
Therefore, the 2016 guidelines recommended empiric antibiotic
coverage for MDR/ESBL organisms should be limited to hospitalacquired pneumonia which is pneumonia contracted by a patient

No signiﬁcant differences were identiﬁed in other outcomes or
subgroup analysis of patients with/without risk factors for
healthcare-associated infections in each antibiotic group (Table 4). These outcomes remained insigniﬁcant after controlling
for potential confounders.

4. Discussion
In the 2005 Infectious Disease Society of America guideline, the
term HCAP was used to deﬁne pneumonia in a patient who is at
Table 2
Microbiological etiology.
Organisms

Cultures

Meropenem

Cefepime

Gram-positive cocci
Gram-negative bacilli
∗
MDR/ESBL (+)
†
CR (+)
CR ()†
Other‡
No growth
Total (n)x

53 (15)
57 (16)
30 (8.3)
17 (4.7)
13 (3.6)
41 (11)
212 (58)
363

20 (13)
27 (18)
20 (13)
12 (7.8)
8 (5.2)
22 (14)
86 (56)
153

17 (14)
17 (14)
7 (5.6)
4 (2.9)
3 (3.2)
12 (9.7)
78 (63)
124

CR = carbapenem-resistant, MDR/ESBL = multi-drug resistant/extended-spectrum beta-lactamase, NA = not applicable.
∗
MDR/ESBL (+) numbers are included in the number of gram-negative bacilli.
†
CR (+/) numbers are included in the number of MDR/ESBL (+).
‡
Other: yeast, gram-positive bacilli, and anaerobic organisms.
x
Summation is greater than total because MDR/ESBL, CR (+/) are included in Gram-negative bacilli.

4

Piperacillin/Tazobactam
16
13
3
1
2
7
48

(19)
(15)
(3.6)
(1.2)
(2.4)
(8.3)
(57)
84

P-value
.303
.528
.012
.038
NA
.295
.371
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Table 3
Logistic regression analysis for developing MDR/ESBL pathogens in cultures.
Variables

P-value

OR (95% CIs)

Admit from SNF/LTAC
History of tracheostomy
History of positive MDR/ESBL pathogens in cultures
Age
Charlson comorbidity index score
Hemiplegia/paraplegia
History of multiple hospital admissions in the past 6 months
No risk factor for healthcare-associated infection
Sex, male
SIRS Overall
∗
1
∗
2
∗
3
∗
4

23.29
1.97
18.35
0.99
1.03
1.29
1.11
0.69
0.61

(3.59–151.4)
(0.51–7.62)
(2.88–117.1)
(0.96–1.03)
(0.92–1.16)
(0.31–5.39)
(0.76–1.33)
(0.05–10.61)
(0.18–1.99)

.001
.328
.002
.692
.591
.730
.591
.790
.409
.595
.850
.270
NA
.238

1.16 (0.24–5.58)
2.72 (0.46–16.00)
NA
3.26 (0.46–23.29)

ESBL = extended-spectrum beta-lactamase, LTAC = long-term acute care, MDR = multi-drug resistant, NA = not applicable, SIRS = systemic inﬂammatory response syndrome, SNIF = skilled nursing facility.
∗
ORs were based on comparison to SIRS 0. Patients with SIRS 3 were too sparse to calculate the CI.
†
The Hosmer–Lemeshow test (HL = 5.513, P = .741).

Table 4
Clinical outcomes of patients.
∗

Clinical outcomes

Overall mortality
Without risk factors
With risk factors
Overall total in-hospital mortality rate
Without risk factors
With risk factors
Overall readmission rate
Without risk factors
With risk factors
Overall median length of hospital days (IQR)
Without risk factors
With risk factors
Overall median length of ICU days (IQR)
Without risk factors
With risk factors
Overall median length of ventilator days (IQR)
Without risk factors
With risk factors

Overall series
Meropenem

Cefepime

Piperacillin/tazobactam

P-value

16 (16%)
13 (18%)
3 (9.7%)
14%
11 (15%)
3 (9.7%)
36%
30 (42%)
7 (23%)
6 (3–11)
6.5 (3–11)
5 (3–11)
3 (1–5)
3 (1–6.5)
2 (1–3)
6 (2–11)
6 (2.75–11.5)
2 (2–13)

16 (18%)
8 (22%)
8 (15%)
17%
7 (19%)
8 (15%)
22%
11 (31%)
8 (15%)
6.5 (3–10)
6.5 (2.25–14)
6.5 (3.25–12.75)
3 (2–9)
3.5 (1.75–10)
3 (2–7.5)
6 (2–11)
5.5 (3–11.25)
4 (2–13.5)

5 (9.3%)
3 (8.6%)
2 (11%)
7.4%
3 (8.6%)
1 (5.3%)
28%
11 (31%)
4 (21%)
6.5 (3–13)
5 (3–14)
7 (3–11)
2 (1–9)
2 (1–9.25)
2 (1–11)
6 (1–28)
4.5 (1.75–20.25)
10 (1–29.5)

.349

.263

.091

.939

.267

.992

ESBL = extended-spectrum beta-lactamase, ICU = intensive care unit, IQR = interquartile range, MDR = multi-drug resistant.
∗
A chi-square test of homogeneity and Kruskal–Wallis test were used for analyses of proportions and medians, respectively. Subgroup analysis for each clinical outcome was performed according to whether the
patient had any risk factors of healthcare-associated infection include MDR/ESBL organisms.

Table 5
Antibiotics prescription pattern and percentage of HCAP exclusion.
Piperacillin/tazobactam
(n = 55)
First antibiotics changed on day one (%)
First antibiotics changed or discontinued day
Total antibiotics day
Respiratory culture returned day
HCAP excluded (%)

24
2
5
4
17

(43.6)
(1–4)
(3–10)
(3–4.25)
(30.9)

Meropenem
(n = 103)
52
1
6
4
15

Values are median (IQR) or number of patients (%).
HCAP = healthcare associated pneumonia, IQR = interquartile range.

5

(50.5)
(1–3)
(3–9)
(3–4.5)
(14.6)

Cefepime
(n = 88)
42
2
6
3
18

(47.7)
(1–3)
(3–12.5)
(3–4)
(20.5)

P-value
.404
.445
.131
.250
.052
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cefepime, 2 [2.3%]; P = .101). These patient histories also explain
the high prescribing rate of meropenem for this group. Third, the
current guidelines strongly emphasize that the best empiric
antimicrobial regimens should be based on local antimicrobial
susceptibilities. Not surprisingly, the diagnosis of HCAP was
strongly associated with the use of carbapenems because our local
antibiogram showed a 77% sensitivity for cefepime and
piperacillin/tazobactam against Pseudomonas aeruginosa (see
Table, Supplemental Digital Content 1, http://links.lww.com/
MD2/A539 which describes bacterial sensitivity patterns of
University of Medical Center of Southern Nevada). This
antibiogram likely impacted the frequency of meropenem chosen
as the initial antibiotic even without a clear diagnosis of HCAP.
Thus, the initial diagnosis of HCAP was the most common reason
for choosing meropenem.
This chart review did not show clear reasoning for this
diagnosis in patients without a clear indication. Frequently, no
clear rationale was documented as to how the diagnosis of HCAP
was made. Fourth, many previous studies suggest that improper
initial antibiotic selection for sepsis increased mortality,[18] but in
our study, there was no difference in clinical outcomes (Table 4).
According to culture results (Table 2), only 10% of the
meropenem group grew MDR/ESBL organisms during the
admission. In other words, 90% of the meropenem group had
negative cultures or grew non-MDR/ESBL organisms. Regardless
of the antibiotic group, more than one-fourth of patients had only
a SIRS score of zero (Table 1). Hence, the many patients did not
meet any criteria for sepsis and could be treated without
antibiotics.[16] According to Welker et al[19] the core quality
measure of sepsis management of time to ﬁrst antibiotic dose in
less than 4 hours of presentation to the emergency department
might increase pressure put on physicians. Thus, due to time
constraints, providers could over-diagnosis pneumonia or
possibly HCAP even when patients do not have risk factors
for healthcare-associated infections.
Williams et al[20] suggested that high Acute Physiology and
Chronic Health Evaluation (APACHE) scores have a positive
relationship with the number of antibiotics prescribed in patients,
however, in our study the severity of disease cannot explain the
ultra-broad spectrum antibiotic coverage because the SIRS score
and Charlson comorbidity index score were not signiﬁcantly
different among the groups. Positive predictors of MDR/ESBL
organisms were only residency in a SNF/LTAC (OR, 23.29; 95%
CI, 3.59–151.4; P = .001) and history of a MDR/ESBL positive
culture (OR, 18.35; 95% CI, 2.88–117.1; P = .002), but multiple
hospital admissions in the past 6 months (OR, 1.11; 95% CI,
0.76–1.33; P = .591), history of tracheostomy (OR 1.97; 95% CI,
0.51–7.62; P = .328), hemiplegia/paraplegia (OR: 1.29; 95% CI,
0.31–5.39; P = .730), Charlson comorbidity index (OR: 1.03;
95% CI, 0.92–1.16; P = .591), and age (OR: 0.99, 95% CI, 0.96–
1.03, P = .692) were not (Table 3). The probable explanation of
this difference between prior studies and our results is the size of
our patient population and characters.[12]
In patients without apparent risk factors for MDR/ESBL
organisms, the drug chosen from among meropenem, cefepime,
and piperacillin/tazobactam was not likely to clinically impact
our patients. It is well known that the use of inappropriate or
unjustiﬁed antibiotics is associated with resistance, adverse
effects, and the development of secondary infections including
Clostridium difﬁcile.
Several limitations exist in our study. This is a single-center
study, so the results may represent local practices that are not

Table 6
SIRS score day 1 and day 3.
Piperacillin/tazobactam (n = 55)
Meropenem (n = 103)
Cefepime (n = 88)

SIRS (day 1)

SIRS (day 3)

1.09 (1.191)
1.22 (1.204)
1.16 (1.027)

0.87 (0.894)
1.06 (1.054)
1.20 (0.966)

∗

P-value
.213
.438
.461

Data are presented in mean (SD).
SD = standard deviation, SIRS = systemic inﬂammatory response syndrome.
∗
P-value were calculated by Wilcoxon Singed Rank Test for related samples.

in a hospital at least 48 to 72 hours after being admitted and
ventilator-associated pneumonia, which is the sub-type of
hospital-acquired pneumonia that occurs in people who are
receiving mechanical ventilation.[10] When a physician prescribes
antibiotics to cover MDR gram-negative pathogens, the regimen
should include piperacillin/tazobactam, cefepime, levoﬂoxacin,
imipenem, or meropenem. The guideline does not have a
preferred antibiotic against pseudomonas because there has
not been deﬁnitive evidence showing that one type of
antipseudomonal agent is preferable over the others. However,
meropenem is generally the drug of choice for MDR/ESBL
infections, but there is also data suggesting that piperacillin/
tazobactam or cefepime may be appropriate for the treatment of
speciﬁc isolates.[15] In 2019, the American Thoracic Society
Infectious Disease Society of America guideline for the treatment
of adults with CAP strongly recommended not using HCAP risk
factors as an indication for extended antibiotic coverage in adults
with CAP.[17]
In our study, regardless of the type of antibiotic initially
prescribed, more than one third of patients did not have a history
of exposure to the healthcare system in the past 90 days.
Surprisingly, 31 (30%) of the meropenem group only met criteria
for CAP (Table 1). This ﬁnding was supported by 15 (14.6%) of
the meropenem group excluded from HCAP diagnosis at the time
of discharge. Median respiratory culture return days were 3 to 4
days in each group. However, most initial antibiotics were
discontinued or changed in the ﬁrst 2 days (Table 5). There was
no signiﬁcant difference between SIRS scores on day 1 and day 3
of admission on all groups (Table 6). This antibiotics prescription
pattern suggests that most initial antibiotics were changed or
discontinued not from respiratory culture results or the patients’
clinical response after a couple of days of hospitalization.
Several factors might inﬂuence a provider’s decision to
prescribe meropenem in the absence of a clear indication. First,
prescribing meropenem could be associated with a patients’
residence. Our study suggests that the residents of a SNF/LTAC is
a risk factor for developing MDR/ESBL organisms in their
cultures (OR, 23.29; 95% CI, 3.59–151.4; P = .001) (Table 3).
Table 1 shows that 37% of patients in the meropenem group
were admitted from a SNF/LTAC. Malcom et al[12] suggested
that risk factors for MDR/ESBL organisms were increasing age, a
history of hospital admissions, residence in a long-term care
faculty, and a high Charlson comorbidity index.[13]
From clinical experience, our emergency department and
admitting physicians may be aware of this trend for positive
cultures of MDR/ESBL organisms among patients admitted from
a SNF/LTAC. Second, although not signiﬁcant, patients in the
meropenem group had more than twice the frequency of a
documented history of MDR/ESBL infections than other groups
(meropenem, 10 [9.7%]; piperacillin/tazobactam, 3 [5.6%];
6
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[3] Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant
enterobacteriaceae: the impact and evolution of a global menace. J Infect
Dis 2017;215:S28–36.
[4] Pollack LA, van Santen KL, Weiner LM, Dudeck MA, Edwards JR,
Srinivasan A. Antibiotic Stewardship Programs in U.S. acute care
hospitals: ﬁndings from the 2014 national healthcare safety network
annual hospital survey. Clin Infect Dis 2016;63:443–9.
[5] Fridkin S, Baggs J, Fagan R, et al. Vital signs: improving antibiotic use
among hospitalized patients. MMWR Morb Mortal Wkly Rep 2014;
63:194–200.
[6] Friedman ND, Temkin E, Carmeli Y. The negative impact of antibiotic
resistance. Clin Microbiol Infect 2016;22:416–22.
[7] Rahal JJ. The role of carbapenems in initial therapy for serious Gramnegative infections. Crit Care 2008;12(Suppl 4):S5.
[8] Livorsi D, Comer A, Matthias MS, Perencevich EN, Bair MJ. Factors
inﬂuencing antibiotic-prescribing decisions among inpatient physicians:
a qualitative investigation. Infect Control Hosp Epidemiol 2015;36:
1065–72.
[9] Kaur A, Bhagat R, Kaur N, et al. A study of antibiotic prescription
pattern in patients referred to tertiary care center in Northern India. Ther
Adv Infect Dis 2018;5:63–8.
[10] American Thoracic S, Infectious Diseases Society of AGuidelines for the
management of adults with hospital-acquired, ventilator-associated, and
healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;
171:388–416.
[11] American College of Chest Physicians/Society of Critical Care Medicine
Consensus Conference: deﬁnitions for sepsis and organ failure and
guidelines for the use of innovative therapies in sepsis. Crit Care Med
1992;20:864–74.
[12] Malcolm W, Fletcher E, Kavanagh K, et al. Risk factors for resistance and
MDR in community urine isolates: population-level analysis using the
NHS Scotland infection intelligence platform. J Antimicrob Chemother
2018;73:223–30.
[13] Aliberti S, Di Pasquale M, Zanaboni AM, et al. Stratifying risk factors for
multidrug-resistant pathogens in hospitalized patients coming from the
community with pneumonia. Clin Infect Dis 2012;54:470–8.
[14] Higgins TL, Kramer AA, Nathanson BH, Copes W, Stark M, Teres D.
Prospective validation of the intensive care unit admission Mortality
Probability Model (MPM0-III). Crit Care Med 2009;37:1619–23.
[15] Kumar ST, Yassin A, Bhowmick T, Dixit D. Recommendations from the
2016 guidelines for the management of adults with hospital-acquired or
ventilator-associated pneumonia. P T 2017;42:767–72.
[16] Valles J, Martin-Loeches I, Torres A, et al. Epidemiology, antibiotic
therapy and clinical outcomes of healthcare-associated pneumonia in
critically ill patients: a Spanish cohort study. Intensive Care Med 2014;
40:572–81.
[17] Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of
adults with community-acquired pneumonia. an ofﬁcial clinical practice
guideline of the American Thoracic Society and Infectious Diseases
Society of America. Am J Respir Crit Care Med 2019;200:e45–67.
[18] Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the
therapy and outcome of ventilator-associated pneumonia. Chest 1997;
111:676–85.
[19] Welker JA, Huston M, McCue JD. Antibiotic timing and errors in
diagnosing pneumonia. Arch Intern Med 2008;168:351–6.
[20] Williams A, Mathai AS, Phillips AS. Antibiotic prescription patterns at
admission into a tertiary level intensive care unit in Northern India. J
Pharm Bioallied Sci 2011;3:531–6.
[21] de Prost N, Razazi K, Brun-Buisson C. Unrevealing culture-negative
severe sepsis. Crit Care 2013;17:1001.

generalizable. Although 13% of the meropenem group grew
MDR/ESBL pathogens, it is unclear what percentage of patients
would truly beneﬁt from meropenem because it is common to
have culture-negative sepsis[21] (Table 2). This study is limited
by its retrospective design and small sample size which has
weakened the statistical power. Regardless, these are intriguing
ﬁndings that serve as hypothesis-generating results for further
investigation using a larger sample sizes or for replication at other
hospitals. Future prospective studies with sufﬁcient sample size
are warranted to conﬁrm our ﬁndings.
In conclusion, for patients with a diagnosis HCAP, a high rate
of overdiagnosis HCAP and inappropriate ultra-broad spectrum
antibiotic (meropenem) were used for initial empiric treatment.
There was no beneﬁt of using carbapenem (meropenem) as a ﬁrstline drug for patients without a deﬁnite risk factor for an MDR/
ESBL infections. Therefore, empiric antibiotics with carbapenems
might be considered for select patients who are admitted from a
SNF/LTAC or have a history of an MDR/ESBL infection or if a
patient is at risk based on local community patterns.
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